Biogen Inc (BIIB) Company Profile & Statistics

Biogen Inc
BIIB
(Nasdaq - US)
Closed
287.34
-4.26 (-1.46%)
in:usd•As of: Feb 02, 2023 15:59 UTC -5
Open
290.06
High
293.14
Low
285.75

About Biogen Inc

CEO

Michel Vounatsos

Headquarters

225 binney street

cambridge, ma 02142, united states

Auditor

PricewaterhouseCoopers LLP

Employees

9,610

Share Holders

479

Website

www.biogen.com

Industry

biotechnology

Sector

health technology

Company Overview

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

Biogen Inc Statistics

Valuation Measures

Market Capitalization ²	41.38B
Enterprise Value	43.98B
Enterprise Value/EBITDA (ttm)	11.31
Price to Earnings Ratio (ttm)	17.12
Price to Book (mrq)	3.29
Price to Sales (ttm)	4.05
Price to Cash (ytd)	10.73

Profitability

Gross Margin (ttm)	77.17%
Operating Margin (ttm)	24.06%
Profit Margin (ttm)	27.89%
Return on Equity (ttm)	21.31%
Return on Invested Capital (ttm)	12.92%
Return on Assets (ttm)	10.24%

Income Statement

Revenue (ttm)	10.36B
Revenue Per Share (ttm)	71.97
Gross Profit (ttm)	8.00B
EBITDA (ttm)³	3.89B
Net Income Avi to Common (ttm)	2.86B
Diluted EPS (ttm)	19.64

Share Statistics

Beta (5Y Monthly)	0.22
52-Week Change	30.51%
S&P500 52-Week Change	-6.65%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	144.00M
Dividend Yield	0.00%
Float ⁴	143.06M
% Held by Insiders	0.65%
% Held by Institutions	84.40%

Balance Sheet

Total Cash (mrq)	4.91B
Total Cash Per Share (mrq)	34.10
Total Debt (mrq)	6.28B
Total Debt/Equity (mrq)	49.18%
Current Ratio (mrq)	2.49%
Quick Ratio (mrq)	2.14%
Book Value Per Share (mrq)	88.66

Cash Flow

Operating Cash Flow Per Share (ytd)	10.77
Free Cash Flow (ytd)	1.99B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Biogen Inc

Trade With A Regulated Broker